Composition
- Active ingredients
- RIVASTIGMINE TARTRATE EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- RIVASTIGMINE TARTRATE EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleThis page
- RIVASTIGMINE TARTRATE EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-003 · Discontinued
- RIVASTIGMINE TARTRATE EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-006 · Discontinued
- RIVASTIGMINE TARTRATE EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-004 · Discontinued
- RIVASTIGMINE TARTRATE EQ 2MG BASE/ML · SolutionNDA021025-001 · Discontinued
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA020823.
At a glance
- Brand name
- Exelon
- Active substance
- rivastigmine tartrate
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Novartis
- Status
- Discontinued
- FDA approval
- 21 Apr 2000
- Application
- NDA020823-005